A PHASE II RANDOMIZED NON COMPARATIVE STUDY ON THE ACTIVITY OF TRABECTEDIN OR GEMCITABINE + DOCETAXEL IN METASTATIC OR LOCALLY RELAPSED UTERINE LEIOMYOSARCOMA PRETREATED WITH CONVENTIONAL CHEMOTHERAPY

Trial Profile

A PHASE II RANDOMIZED NON COMPARATIVE STUDY ON THE ACTIVITY OF TRABECTEDIN OR GEMCITABINE + DOCETAXEL IN METASTATIC OR LOCALLY RELAPSED UTERINE LEIOMYOSARCOMA PRETREATED WITH CONVENTIONAL CHEMOTHERAPY

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jul 2018

At a glance

  • Drugs Trabectedin (Primary) ; Docetaxel; Gemcitabine
  • Indications Leiomyosarcoma; Uterine leiomyoma
  • Focus Therapeutic Use
  • Acronyms TAUL
  • Most Recent Events

    • 30 Jul 2018 Primary endpoint (Progression free rate at 6-month) has been met, as per the results published in the British Journal of Cancer
    • 30 Jul 2018 Results (n=126) evaluating safety and efficacy published in the British Journal of Cancer
    • 05 Dec 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top